View Older Stories View More Recent Stories

Aug 16, 2024 08:31AM Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
Aug 16, 2024 08:30AM Personalis and Tempus Announce Expanded Collaboration
Aug 7, 2024 04:01PM Personalis Reports Second Quarter 2024 Financial Results
Jul 31, 2024 04:01PM Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Jul 24, 2024 04:01PM Personalis to Announce Second Quarter 2024 Financial Results
Jul 11, 2024 09:00AM Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Jun 18, 2024 04:01PM Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
Jun 13, 2024 08:00AM Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
Jun 4, 2024 04:05PM ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
May 31, 2024 09:05AM Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
May 22, 2024 09:05AM Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
May 17, 2024 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2024 04:01PM Personalis Reports First Quarter 2024 Financial Results
Apr 24, 2024 04:01PM Personalis to Announce First Quarter 2024 Financial Results
Mar 28, 2024 04:01PM Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 28, 2024 09:00AM Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Mar 26, 2024 09:00AM Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Mar 19, 2024 04:43PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2024 04:01PM Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 14, 2024 04:01PM Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
Jan 31, 2024 04:01PM Personalis to Participate at Upcoming Investor Conferences
Jan 30, 2024 09:00AM Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Jan 17, 2024 04:15PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 16, 2024 09:05AM Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Jan 5, 2024 09:10AM Personalis (PSNL) Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
Jan 5, 2024 09:05AM Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
Dec 4, 2023 09:16AM Personalis, Inc. (PSNL) discloses reduction in headcount impacting approximately 20%
Dec 4, 2023 09:15AM Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
Nov 28, 2023 04:22PM Personalis, Inc. (PSNL) and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Nov 28, 2023 04:15PM Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Nov 16, 2023 04:06PM Myriad Genetics (MYGN) and Personalis Partner to Market Solutions to Pharma Customers
Nov 16, 2023 04:05PM Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Nov 7, 2023 04:01PM Personalis Reports Third Quarter 2023 Financial Results
Oct 26, 2023 08:15AM Personalis (PSNL) Launches NeXT Personal Dx for Early Access Clinical Use
Oct 26, 2023 08:15AM Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
Oct 24, 2023 04:01PM Personalis to Announce Third Quarter 2023 Financial Results
Oct 21, 2023 04:25AM Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
Oct 19, 2023 07:15AM Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
Oct 18, 2023 07:15AM Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
Aug 29, 2023 04:01PM Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Aug 24, 2023 07:01PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2023 04:01PM Personalis Reports Second Quarter 2023 Financial Results
Aug 1, 2023 04:01PM Personalis to Participate at Upcoming Investor Conferences
Jul 25, 2023 04:01PM Personalis to Announce Second Quarter 2023 Financial Results
Jun 26, 2023 05:04PM Personalis (PSNL) Files Second Patent Infringement Suit Against Foresight Diagnostics
Jun 26, 2023 05:00PM Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
Jun 14, 2023 04:54AM Personalis, Inc. (PSNL) Appoints Kenneth J. Widder to its Board
Jun 13, 2023 07:01PM Dr. Kenneth J. Widder Joins Personalis Board of Directors
May 30, 2023 08:00AM Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
May 16, 2023 08:00AM Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
View More Recent Stories View Older Stories